D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey

JD Elsworth, MS Lawrence, RH Roth, JR Taylor, RB Mailman, DE Nichols, MH Lewis and DE Redmond

Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.

Previous studies have revealed the involvement of a dopaminergic link in the regulation of spontaneous eye blink rate in primates. Based on the effect of dopamine D2 receptor-selective drugs and the anecdotal failure of the partial D1 agonist, SKF 38393, to alter blink rate in monkeys, it was assumed that D1 dopamine receptors did not control blink rate. The recent availability of dihydrexidine, a full D1 agonist, prompted us to reevaluate the role of D1 and D2 receptors in the regulation of blink rate. African green monkeys (n = 5) were used in all studies. Dihydrexidine produced a rapid and dose-dependent (up to 1 mg/kg, i.m.) increase in blink rate. The elevation in blink rate elicited by 0.3 mg/kg dihydrexidine was completely reversed by prior administration of a specific D1 antagonist, SCH 23390 (0.01 mg/kg, i.m.), but was unaffected by prior administration of a specific D2 antagonist, remoxipride (1 mg/kg, i.m.). Treatment with the specific D2 agonist, (+)-4-propyl-9-hydroxynaphthoxazine, led to a rapid and dose- dependent (up to 0.01 mg/kg, i.m.) increase in blink rate. The raised blink rate produced by (+)-4-propyl-9-hydroxynaphthoxazine (0.001 mg/kg) was abolished by pretreatment with remoxipride, but was not influenced by pretreatment with SCH 23390. These data indicate that spontaneous blink rate in the primate can be regulated by both D1 and D2 dopamine receptors. Furthermore, the receptor subtypes appear to affect blink rate in the same direction, yet function independently. Measurement of blink rate may provide a noninvasive method to assess the potency and selectivity of dopamine agonists and antagonists in primates.

Volume 259, Issue 2, pp. 595-600, 11/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				C. Mohr, P. S. Sandor, T. Landis, M. Fathi, and P. Brugger Blinking and schizotypal thinking J Psychopharmacol, September 1, 2005; 19(5): 513 - 520. [Abstract] [PDF]

				E. M. Jutkiewicz and J. Bergman Effects of Dopamine D1 Ligands on Eye Blinking in Monkeys: Efficacy, Antagonism, and D1/D2 Interactions J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1008 - 1015. [Abstract] [Full Text] [PDF]

				J. van der Post, P. P. de Waal, M. L. de Kam, A. F. Cohen, and J. M. A. van Gerven No evidence of the usefulness of eye blinking as a marker for central dopaminergic activity J Psychopharmacol, March 1, 2004; 18(1): 109 - 114. [Abstract] [PDF]

				R. S. Baker, S. M. Radmanesh, and K. M. Abell The Effect of Apomorphine on Blink Kinematics in Subhuman Primates with and without Facial Nerve Palsy Invest. Ophthalmol. Vis. Sci., September 1, 2002; 43(9): 2933 - 2938. [Abstract] [Full Text] [PDF]

				I. Bodis-Wollner, S. F. Bucher, and K. C. Seelos Cortical activation patterns during voluntary blinks and voluntary saccades Neurology, November 1, 1999; 53(8): 1800 - 1800. [Abstract] [Full Text]